Curi Bio Company

Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics. By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
Industry: Data processing
Headquarters: Seattle, Washington, United States
Founded Date: 2015-01-01
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 3
Total Funding: 16000000
Estimated Revenue: Less than $1M
Last Funding Date: 2021-12-29
Last Funding Type: Series A

Visit Website
contact@curibio.com
https://twitter.com/curi_bio
Register and Claim Ownership